Pasithea Therapeutics (KTTA) Competitors $0.79 -0.04 (-5.21%) Closing price 04:00 PM EasternExtended Trading$0.80 +0.01 (+1.53%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock KTTA vs. CALC, NNVC, CMMB, CARA, TENX, CYTH, OVID, ENLV, GDTC, and ELEVShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include CalciMedica (CALC), NanoViricides (NNVC), Chemomab Therapeutics (CMMB), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Cyclo Therapeutics (CYTH), Ovid Therapeutics (OVID), Enlivex Therapeutics (ENLV), CytoMed Therapeutics (GDTC), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Its Competitors CalciMedica NanoViricides Chemomab Therapeutics Cara Therapeutics Tenax Therapeutics Cyclo Therapeutics Ovid Therapeutics Enlivex Therapeutics CytoMed Therapeutics Elevation Oncology CalciMedica (NASDAQ:CALC) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings. Does the MarketBeat Community prefer CALC or KTTA? CalciMedica received 16 more outperform votes than Pasithea Therapeutics when rated by MarketBeat users. Likewise, 94.74% of users gave CalciMedica an outperform vote while only 40.00% of users gave Pasithea Therapeutics an outperform vote. CompanyUnderperformOutperformCalciMedicaOutperform Votes1894.74% Underperform Votes15.26%Pasithea TherapeuticsOutperform Votes240.00% Underperform Votes360.00% Which has higher earnings & valuation, CALC or KTTA? CalciMedica is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalciMedicaN/AN/A-$34.36M-$1.56-1.10Pasithea TherapeuticsN/AN/A-$15.96M-$10.60-0.07 Which has more volatility and risk, CALC or KTTA? CalciMedica has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Do analysts prefer CALC or KTTA? CalciMedica presently has a consensus price target of $18.00, indicating a potential upside of 946.51%. Given CalciMedica's stronger consensus rating and higher probable upside, analysts plainly believe CalciMedica is more favorable than Pasithea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Pasithea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CALC or KTTA more profitable? Pasithea Therapeutics' return on equity of -81.57% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets CalciMedicaN/A -164.24% -103.53% Pasithea Therapeutics N/A -81.57%-74.31% Do insiders and institutionals hold more shares of CALC or KTTA? 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 41.5% of CalciMedica shares are owned by insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor CALC or KTTA? In the previous week, CalciMedica and CalciMedica both had 4 articles in the media. Pasithea Therapeutics' average media sentiment score of 0.72 beat CalciMedica's score of 0.62 indicating that Pasithea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCalciMedica beats Pasithea Therapeutics on 8 of the 14 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.85M$6.88B$5.58B$8.50BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-0.078.5527.1919.64Price / SalesN/A262.61408.78152.17Price / CashN/A65.8538.3234.64Price / Book0.036.536.974.60Net Income-$15.96M$143.48M$3.23B$248.06M7 Day Performance-11.27%0.20%-0.88%-1.02%1 Month Performance-8.60%10.93%7.81%3.51%1 Year Performance-86.21%2.46%31.53%12.68% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea Therapeutics1.5903 of 5 stars$0.79-5.2%N/A-85.7%$5.85MN/A-0.073Short Interest ↓Gap DownCALCCalciMedica2.7282 of 5 stars$1.85+3.4%$18.00+873.0%-65.4%$25.85MN/A-1.7130News CoverageNNVCNanoViricides0.1253 of 5 stars$1.53+0.7%N/A-38.4%$24.59MN/A-2.1220Short Interest ↑CMMBChemomab Therapeutics3.5804 of 5 stars$1.30-1.5%$8.50+553.8%+11.4%$24.51MN/A-1.3020Positive NewsCARACara Therapeutics0.2852 of 5 starsN/A$36.00+∞N/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeTENXTenax Therapeutics1.6477 of 5 stars$5.78-1.4%$17.50+202.8%+78.4%$23.98MN/A-2.339Positive NewsCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809OVIDOvid Therapeutics4.3922 of 5 stars$0.32-3.0%$2.78+766.8%-91.0%$22.83M$548K-0.6860High Trading VolumeENLVEnlivex Therapeutics3.4548 of 5 stars$0.96+2.1%$10.00+941.7%-32.4%$22.71MN/A-0.9870News CoverageGDTCCytoMed Therapeutics2.5962 of 5 stars$2.08-0.7%$5.00+141.0%+2.4%$22.70M$69.50K0.00N/APositive NewsGap UpELEVElevation Oncology3.3897 of 5 stars$0.38-0.4%$3.39+784.7%-88.7%$22.67MN/A-0.4740Trending NewsAnalyst ForecastShort Interest ↓Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies CalciMedica Alternatives NanoViricides Alternatives Chemomab Therapeutics Alternatives Cara Therapeutics Alternatives Tenax Therapeutics Alternatives Cyclo Therapeutics Alternatives Ovid Therapeutics Alternatives Enlivex Therapeutics Alternatives CytoMed Therapeutics Alternatives Elevation Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KTTA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KTTA Stock Free KTTA Stock Alerts